GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.0% ·
share flow +4.0% ·
net new positions -5.3%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | — |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | — | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | — | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | — |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | — | 24.13M | $697.01M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 12.17M | — | $633.22M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 10.98M | — | $571.37M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 3 | Baillie Gifford ✦ | 4.81M | -5.0% | $250.30M | 0.2% | ▼ Trim | 5 | SEC ↗ ×4 |
| 4 | Citadel Advisors ✦ | 2.94M | -18.3% | $152.92M | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 2.92M | +0.5% | $152.01M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 2.84M | +1.4% | $147.78M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | ARK Investment Management ✦ | 2.82M | +100.4% | $146.93M | 1.1% | ▲ Add | 5 | SEC ↗ |
| 8 | Millennium Management ✦ | 2.72M | +148.2% | $141.65M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.92M | -3.6% | $100.07M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 10 | Two Sigma Investments ✦ | 1.85M | +1.6% | $96.51M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 1.77M | +180.5% | $91.88M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 12 | Norges Bank ✦ (passive) | 1.23M | +1.6% | $64.14M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 987.67K | — | $51.40M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 14 | Renaissance Technologies ✦ | 675.20K | +9.5% | $35.14M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 307.31K | -63.7% | $15.99M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 80.13K | +12.0% | $4.17M | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 17 | PRIMECAP Management ✦ | 65.99K | +51.1% | $3.43M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 56.30K | -92.8% | $2.93M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 3.87K | -23.7% | $201,395 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $7.52M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 481 holders, 137.05M shares, $11.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 826 sh · $144,550
Director · 116 sh · $20,300
Director · 1.30K sh · $229,236
Director · 3.30K sh · $578,888
Director · 1.10K sh · $192,432
Director · 971 sh · $172,330
Officer · 7.74K sh · $1.38M
Officer · 4.00K sh · $632,193
Officer, Director · 7.59K sh · $1.29M
Officer, Director · 20.89K sh · $3.53M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology